Exact Mass: 496.2758

Exact Mass Matches: 496.2758

Found 42 metabolites which its exact mass value is equals to given mass value 496.2758, within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error 0.0002 dalton.

APGPR Enterostatin

(2S)-2-({[(2S)-1-[2-({[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)acetyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-5-carbamimidamidopentanoate

C21H36N8O6 (496.2758)


Enterostatin APGPR (Ala-Pro-Gly-Pro-Arg) is a pentapeptide released from procolipase during fat digestion. In addition to the pancreas, enterostatin-immunoreactive cells are also present in the antrum and proximal small intestine. Enterostatin selectively reduces fat intake, decreases insulin secretion, and also increases energy expenditure by activating brown adipose tissue during high-fat feeding. Enterostatins are pentapeptides derived from the NH2-terminus of procolipase after tryptic cleavage and belong to the family of gut-brain peptides. Enterostatin is generated by the action of trypsin on procolipase in the intestinal lumen. Its structure is highly conserved in evolution, with an amino acid sequence of XPXPR. Three enterostatin sequences, Val-Pro-Asp-Pro-Arg (VPDPR), Val-Pro-Gly-Pro-Arg (VPGPR), and Ala-Pro-Gly-Pro-Arg (APGPR), have been studied extensively and shown to be almost equally effective in their ability to decrease dietary fat preference. Enterostatins are selective inhibitors of appetite, particularly of fat intake. Hyperenterostatinemia in obesity is probably secondary to enterostatin resistance; therefore, the regulatory system is producing more enterostatin to counteract the resistance. This is very similar to hyperinsulinemia and hyperleptinemia in obesity. The diminution in the meal-induced secretion of enterostatin in obesity suggests a delay in the appearance of satiety, leading to increased caloric intake. In rats enterostatin decreases body weight by decreasing fat-calorie intake and increasing the sympathetic firing rate of the nerves in interscapular brown adipose tissue. Enterostatin levels are elevated in the plasma of obese women, and enterostatin secretion is diminished after satiety. Oral administration of enterostatin, however, has no effect on food intake, energy expenditure, or body weight in subjects with a preference for a high-fat diet experiencing a negative energy and fat balance, and the physiology of enterostatin in humans remains to be defined. (PMID: 10084574, 9526102, 8886249) [HMDB] Enterostatin APGPR (Ala-Pro-Gly-Pro-Arg) is a pentapeptide released from procolipase during fat digestion. In addition to the pancreas, enterostatin-immunoreactive cells are also present in the antrum and proximal small intestine. Enterostatin selectively reduces fat intake, decreases insulin secretion, and also increases energy expenditure by activating brown adipose tissue during high-fat feeding. Enterostatins are pentapeptides derived from the NH2-terminus of procolipase after tryptic cleavage and belong to the family of gut-brain peptides. Enterostatin is generated by the action of trypsin on procolipase in the intestinal lumen. Its structure is highly conserved in evolution, with an amino acid sequence of XPXPR. Three enterostatin sequences, Val-Pro-Asp-Pro-Arg (VPDPR), Val-Pro-Gly-Pro-Arg (VPGPR), and Ala-Pro-Gly-Pro-Arg (APGPR), have been studied extensively and shown to be almost equally effective in their ability to decrease dietary fat preference. Enterostatins are selective inhibitors of appetite, particularly of fat intake. Hyperenterostatinemia in obesity is probably secondary to enterostatin resistance; therefore, the regulatory system is producing more enterostatin to counteract the resistance. This is very similar to hyperinsulinemia and hyperleptinemia in obesity. The diminution in the meal-induced secretion of enterostatin in obesity suggests a delay in the appearance of satiety, leading to increased caloric intake. In rats enterostatin decreases body weight by decreasing fat-calorie intake and increasing the sympathetic firing rate of the nerves in interscapular brown adipose tissue. Enterostatin levels are elevated in the plasma of obese women, and enterostatin secretion is diminished after satiety. Oral administration of enterostatin, however, has no effect on food intake, energy expenditure, or body weight in subjects with a preference for a high-fat diet experiencing a negative energy and fat balance, and the physiology of enterostatin in humans remains to be defined. (PMID: 10084574, 9526102, 8886249). Enterostatin, human, mouse, rat is a pentapeptide that reduces fat intake. Enterostatin, human, mouse, rat is a pentapeptide that reduces fat intake.

   

Val Lys Gly His Gly

Val Lys Gly His Gly

C21H36N8O6 (496.2758)


   

His Lys Asn Val

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]hexanamido]-3-carbamoylpropanamido]-3-methylbutanoic acid

C21H36N8O6 (496.2758)


   

His Lys Val Asn

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]hexanamido]-3-methylbutanamido]-3-carbamoylpropanoic acid

C21H36N8O6 (496.2758)


   

His Asn Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]hexanamido]-3-methylbutanoic acid

C21H36N8O6 (496.2758)


   

His Asn Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]-3-methylbutanamido]hexanoic acid

C21H36N8O6 (496.2758)


   

His Val Lys Asn

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanamido]hexanamido]-3-carbamoylpropanoic acid

C21H36N8O6 (496.2758)


   

His Val Asn Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanamido]-3-carbamoylpropanamido]hexanoic acid

C21H36N8O6 (496.2758)


   

Lys His Asn Val

(2S)-2-[(2S)-3-carbamoyl-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-imidazol-4-yl)propanamido]propanamido]-3-methylbutanoic acid

C21H36N8O6 (496.2758)


   

Lys His Val Asn

(2S)-3-carbamoyl-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanamido]propanoic acid

C21H36N8O6 (496.2758)


   

Lys Asn His Val

(2S)-2-[(2S)-2-[(2S)-3-carbamoyl-2-[(2S)-2,6-diaminohexanamido]propanamido]-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanoic acid

C21H36N8O6 (496.2758)


   

Lys Asn Val His

(2S)-2-[(2S)-2-[(2S)-3-carbamoyl-2-[(2S)-2,6-diaminohexanamido]propanamido]-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanoic acid

C21H36N8O6 (496.2758)


   

Lys Val His Asn

(2S)-3-carbamoyl-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanamido]propanoic acid

C21H36N8O6 (496.2758)


   

Lys Val Asn His

(2S)-2-[(2S)-3-carbamoyl-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]propanamido]-3-(1H-imidazol-4-yl)propanoic acid

C21H36N8O6 (496.2758)


   

Asn His Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]hexanamido]-3-methylbutanoic acid

C21H36N8O6 (496.2758)


   

Asn His Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanamido]hexanoic acid

C21H36N8O6 (496.2758)


   

Asn Lys His Val

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-carbamoylpropanamido]hexanamido]-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanoic acid

C21H36N8O6 (496.2758)


   

Asn Lys Val His

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-carbamoylpropanamido]hexanamido]-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanoic acid

C21H36N8O6 (496.2758)


   

Asn Val His Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanamido]hexanoic acid

C21H36N8O6 (496.2758)


   

Asn Val Lys His

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-methylbutanamido]hexanamido]-3-(1H-imidazol-4-yl)propanoic acid

C21H36N8O6 (496.2758)


   

Pro Pro Gln Arg

(2S)-5-carbamimidamido-2-[(2S)-4-carbamoyl-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}butanamido]pentanoic acid

C21H36N8O6 (496.2758)


   

Pro Pro Arg Gln

(2S)-2-[(2S)-5-carbamimidamido-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}pentanamido]-4-carbamoylbutanoic acid

C21H36N8O6 (496.2758)


   

Pro Gln Pro Arg

(2S)-5-carbamimidamido-2-{[(2S)-1-[(2S)-4-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]butanoyl]pyrrolidin-2-yl]formamido}pentanoic acid

C21H36N8O6 (496.2758)


   

Pro Gln Arg Pro

(2S)-1-[(2S)-5-carbamimidamido-2-[(2S)-4-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]pentanoyl]pyrrolidine-2-carboxylic acid

C21H36N8O6 (496.2758)


   

Pro Arg Pro Gln

(2S)-2-{[(2S)-1-[(2S)-5-carbamimidamido-2-[(2S)-pyrrolidin-2-ylformamido]pentanoyl]pyrrolidin-2-yl]formamido}-4-carbamoylbutanoic acid

C21H36N8O6 (496.2758)


   

Pro Arg Gln Pro

(2S)-1-[(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-pyrrolidin-2-ylformamido]pentanamido]-4-carbamoylbutanoyl]pyrrolidine-2-carboxylic acid

C21H36N8O6 (496.2758)


   

Gln Pro Pro Arg

(2S)-2-{[(2S)-1-{[(2S)-1-[(2S)-2-amino-4-carbamoylbutanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanoic acid

C21H36N8O6 (496.2758)


   

Gln Pro Arg Pro

(2S)-1-[(2S)-2-{[(2S)-1-[(2S)-2-amino-4-carbamoylbutanoyl]pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanoyl]pyrrolidine-2-carboxylic acid

C21H36N8O6 (496.2758)


   

Gln Arg Pro Pro

(2S)-1-{[(2S)-1-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

C21H36N8O6 (496.2758)


   

Arg Pro Pro Gln

(2S)-2-{[(2S)-1-{[(2S)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}-4-carbamoylbutanoic acid

C21H36N8O6 (496.2758)


   

Arg Pro Gln Pro

(2S)-1-[(2S)-2-{[(2S)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}-4-carbamoylbutanoyl]pyrrolidine-2-carboxylic acid

C21H36N8O6 (496.2758)


   

Arg Gln Pro Pro

(2S)-1-{[(2S)-1-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-carbamoylbutanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

C21H36N8O6 (496.2758)


   

Val His Lys Asn

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanamido]hexanamido]-3-carbamoylpropanoic acid

C21H36N8O6 (496.2758)


   

Val His Asn Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]hexanoic acid

C21H36N8O6 (496.2758)


   

Val Lys His Asn

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanoic acid

C21H36N8O6 (496.2758)


   

Val Lys Asn His

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanoic acid

C21H36N8O6 (496.2758)


   

Val Asn His Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]hexanoic acid

C21H36N8O6 (496.2758)


   

Val Asn Lys His

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-carbamoylpropanamido]hexanamido]-3-(1H-imidazol-4-yl)propanoic acid

C21H36N8O6 (496.2758)


   

VKGHG

Val Lys Gly His Gly

C21H36N8O6 (496.2758)


   

APGPR

N2-[1-[N-(1-L-Alanyl-L-prolyl)glycyl]-L-prolyl] L-arginine

C21H36N8O6 (496.2758)


Enterostatin, human, mouse, rat is a pentapeptide that reduces fat intake. Enterostatin, human, mouse, rat is a pentapeptide that reduces fat intake.

   

Native Bovine Alkaline Phosphatase

Native Bovine Alkaline Phosphatase

C21H36N8O6 (496.2758)


   

APGPR Enterostatin

(2S)-2-[[(2S)-1-[2-[[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid

C21H36N8O6 (496.2758)


Enterostatin, human, mouse, rat is a pentapeptide that reduces fat intake. Enterostatin, human, mouse, rat is a pentapeptide that reduces fat intake.